标题
Current and new pharmacotherapy options for non-alcoholic steatohepatitis
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-15
出版商
Informa UK Limited
发表日期
2020-04-02
DOI
10.1080/14656566.2020.1744564
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results
- (2020) K.J. Lucas et al. DIGESTIVE AND LIVER DISEASE
- Hepatocyte Deletion of Triglyceride‐Synthesis Enzyme DGAT 2 Reduces Steatosis without Increasing Inflammation or Fibrosis
- (2019) Nina L. Gluchowski et al. HEPATOLOGY
- Novel MRI assessment of treatment response in HIV ‐associated NAFLD : a randomized trial of an SCD 1 inhibitor ( ARRIVE Trial)
- (2019) Veeral H. Ajmera et al. HEPATOLOGY
- Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
- (2019) Philip Newsome et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
- (2019) Fernando Bril et al. DIABETES CARE
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 drug pipelines in the treatment of NASH
- (2019) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way
- (2019) Ludovico Abenavoli et al. International Journal of Environmental Research and Public Health
- Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design
- (2019) Quentin M. Anstee et al. Contemporary Clinical Trials
- A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
- (2019) Marcos Pedrosa et al. Contemporary Clinical Trials
- Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
- (2018) K. Cusi et al. DIABETIC MEDICINE
- MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis
- (2018) Jerry R. Colca et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study
- (2018) A.M. Diehl et al. JOURNAL OF HEPATOLOGY
- Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
- (2018) Benaïssa Boubia et al. JOURNAL OF MEDICINAL CHEMISTRY
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- FGF-19 agonism for NASH: a short study of a long disease
- (2018) Michael Charlton LANCET
- Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib
- (2018) Zobair M. Younossi et al. LIVER INTERNATIONAL
- Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH
- (2018) Daniela Carmen Oniciu et al. PLoS One
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- (2018) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis
- (2018) Melissa Palmer et al. BMC Pharmacology & Toxicology
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)
- (2018) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
- (2018) Aruna D. Pradhan et al. AMERICAN HEART JOURNAL
- Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis
- (2018) Eduardo Vilar-Gomez et al. HEPATOLOGY
- Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
- (2018) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
- (2018) Edgar D. Charles et al. Obesity
- JKB-122 is effective, alone or in combination with prednisolone in Con A-induced hepatitis
- (2017) Mei-Chi Hsu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation
- (2017) David Goldberg et al. GASTROENTEROLOGY
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
- (2017) Rohit Loomba et al. HEPATOLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice
- (2017) M. Pilar Valdecantos et al. HEPATOLOGY
- Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus
- (2017) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to suppression of hepatic de novo lipogenesis and significant improvements in MRI-PDFF, MRE, and markers of fibrosis after 12 weeks of therapy in patients with NASH
- (2017) E.J. Lawitz et al. JOURNAL OF HEPATOLOGY
- Estimation of serum “true collagen type III formation” (Pro-C3) levels as a marker of non-alcoholic steatohepatitis in a prospective cohort
- (2017) D.J. Leeming et al. JOURNAL OF HEPATOLOGY
- Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
- (2017) Hannes Hagström et al. JOURNAL OF HEPATOLOGY
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
- (2017) Mukul R. Jain et al. LIVER INTERNATIONAL
- The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease
- (2017) Sheng Zhong et al. MEDICINE
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
- (2017) Satish K. Garg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide, lipid-lowering drugs, and NAFLD
- (2017) Niki Katsiki et al. Lancet Diabetes & Endocrinology
- Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
- (2017) Yasushi Honda et al. Scientific Reports
- Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis
- (2016) S. A. Harrison et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
- (2016) Nadira Ruzehaji et al. ANNALS OF THE RHEUMATIC DISEASES
- Understanding the Physiology of FGF21
- (2016) Ffolliott Martin Fisher et al. Annual Review of Physiology
- Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
- (2016) Shun Ishibashi et al. ATHEROSCLEROSIS
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients
- (2016) Evan Stein et al. Journal of Clinical Lipidology
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
- (2016) Frederik Nevens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet–fed mice
- (2016) Anuradha Rao et al. Science Translational Medicine
- Metabolic aspects of adult patients with nonalcoholic fatty liver disease
- (2016) Ludovico Abenavoli et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Specific inhibition of bile acid transport alters plasma lipids and GLP-1
- (2015) Mats Rudling et al. BMC Cardiovascular Disorders
- Bile Acids as Hormones: The FXR-FGF15/19 Pathway
- (2015) Steven A. Kliewer et al. DIGESTIVE DISEASES
- Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
- (2015) Chiara Degirolamo et al. NATURE REVIEWS DRUG DISCOVERY
- The Impact of PNPLA3 rs738409 Genetic Polymorphism and Weight Gain ≥10 kg after Age 20 on Non-Alcoholic Fatty Liver Disease in Non-Obese Japanese Individuals
- (2015) Kenichi Nishioji et al. PLoS One
- Human lysyl oxidase-like 2
- (2014) Hee-Jung Moon et al. BIOORGANIC CHEMISTRY
- Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
- (2014) M. Zhou et al. CANCER RESEARCH
- Therapeutic Strategies for Metabolic Diseases: Small-Molecule Diacylglycerol Acyltransferase (DGAT) Inhibitors
- (2014) Ravi Naik et al. ChemMedChem
- The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease
- (2014) Rifaat Safadi et al. Clinical Gastroenterology and Hepatology
- CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study
- (2014) N. A. Di Prospero et al. DIABETES OBESITY & METABOLISM
- Roles for Chemokines in Liver Disease
- (2014) Fabio Marra et al. GASTROENTEROLOGY
- Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)
- (2014) Yuichiro Eguchi et al. HEPATOLOGY RESEARCH
- Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis
- (2014) Chris J. Weston et al. JOURNAL OF CLINICAL INVESTIGATION
- Inventing new medicines: The FGF21 story
- (2014) Alexei Kharitonenkov et al. Molecular Metabolism
- Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways
- (2013) Daniel F. Vatner et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist
- (2013) Rebecca Taub et al. ATHEROSCLEROSIS
- The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
- (2013) Gregory Gaich et al. Cell Metabolism
- Peroxisome proliferator-activated receptor δ
- (2013) Lazar A. Bojic et al. CURRENT OPINION IN LIPIDOLOGY
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- Decoding cell death signals in liver inflammation
- (2013) Catherine Brenner et al. JOURNAL OF HEPATOLOGY
- Malonyl-CoA: the regulator of fatty acid synthesis and oxidation
- (2012) Daniel W. Foster JOURNAL OF CLINICAL INVESTIGATION
- Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study
- (2012) Yuichiro Eguchi et al. JOURNAL OF GASTROENTEROLOGY
- Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells
- (2011) T. Adar et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- The regulation of inflammation by galectin-3
- (2009) Neil C. Henderson et al. IMMUNOLOGICAL REVIEWS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now